Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer

Journal of the National Cancer Institute

Volumn 91, Issue 4, 1999, Pages 339-346

  Buller, Richard E ^a,b   Sood, Anil K ^a   Lallas, Thomas ^a   Buekers, Thomas ^a   Skilling, Jeffrey S ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b Division of Gynecologic Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; DNA; TRINUCLEOTIDE;

ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE MUTATION; GERM LINE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; OVARY CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; TRINUCLEOTIDE REPEAT; TUMOR SUPPRESSOR GENE; X CHROMOSOME INACTIVATION;

EID: 0033577046     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.4.339     Document Type: Article

References (58)

1. Gartler SM, Ziprowski L, Krakowski A, Ezra R, Szeinberg A, Adam A. Glucose 6 phosphate dehydrogenase mosaicism as a tracer in the study of hereditary multiple trichoepithelioma. Am J Human Genetics 1966;18: 282-7.
2. Beutler E, Collins Z, Irwin LE. Value of genetic variants of glucose-6-phosphate dehydrogenase in tracing the origin of malignant tumors. N Engl J Med 1967;276:389-91.
3. Smith JW, Townsend DE, Sparks RS. Genetic variants of glucose-6-phosphate dehydrogenase in the study of carcinoma of the cervix. Cancer 1971;28:529-32.
4. Lyon M. X-chromosome inactivation as a system of gene dosage compensation to regulate gene therapy. Prog Nucleic Acid Res Mol Biol 1989;36: 119-30.
5. Gartler SM, Riggs AD. Mammalian X-chromosome inactivation. Ann Rev Genet 1983;17:155-90.
6. Jacobs IJ, Kohler MF, Wiseman RW, Marks JR, Whitaker R, Kerns BA, et al. Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J Natl Cancer Inst 1992;84:1793-8.
7. Tsao SW, Mok CH, Knapp RC, Oike K, Muto MG, Welch WR, et al. Molecular genetic evidence of a unifocal origin for human serous ovarian carcinomas. Gynecol Oncol 1993;48:5-10.
8. Enomoto T, Fujita M, Inoue M, Tanizawa O, Nomora T, Shroyer KR. Analysis of clonality by amplification of short tandem repeats. Carcinomas of the female reproductive tract. Diagn Mol Pathol 1994;3:292-7.
9. Pejovic T, Heim S, Mendahl N, Elmfors B, Furgyik S, Floderus UM, et al. Bilateral ovarian carcinoma: cytogenetic evidence of unicentric origin. Int J Cancer 1991;47;358-61.
10. Allen RC, Zoghbi HY, Moseley AB, Rosenblatt HM, Belmont JW. Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen receptor gene correlates with X chromosome inactivation. Am J Hum Genet 1992;51:1229-39.
11. Razin A, Riggs AD. DNA methylation and gene function. Science 1980; 210:604-10.
12. Gale RE, Wheadon H, Linch DC. X-chromosome inactivation patterns using HPRT and PGK polymorphisms in haematologically normal and post-chemotherapy females. Br J Haematol 1991;79:193-7.
13. Vogelstein B, Fearon ER, Hamilton SR, Preisinger AC, Willard HF, Michelson AM, et al. Clonal analysis using recombinant DNA probes from the X-chromosome. Cancer Res 1987;47:4806-13.
14. Naumova AK, Plenge RM, Bird LM, Leppert M, Morgan K, Willard HF, et al. Heritability of X chromosome - inactivation phenotype in a large family. Am J Hum Genet 1996;58:1111-9.
15. Plenge RM, Hendrich BD, Schwartz C, Arena JF, Naumova A, Sapienza C, et al. A promoter mutation in the XIST gene in two unrelated families with skewed X-chromosome inactivation. Nat Genet 1997;17:353-6.
16. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971;68:820-3.
17. Knudson AG Jr. Antioncogenes and human cancer. Proc Natl Acad Sci USA 1993;90:10914-21.
18. Hollingsworth RE, Lee WH. Tumor suppressor genes: new prospects for cancer research. J Natl Cancer Inst 1991;83:91-6.
19. Li FP, Garber JE, Friend SH, Strong LH, Patenaude AF, Juengst ET, et al. Recommendations on predictive testing for germ line p53 mutations along cancer-prone individuals. J Natl Cancer Inst 1992;84: 1156-60.
20. Boyd J, Rubin SC. Hereditary ovarian cancer: molecular genetics and clinical implications. Gynecol Oncol 1997;64:196-206.
21. Couch FJ, Weber BL. Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Breast Cancer Information Core. Hum Mutat 1996;8:8-18.
22. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1996;12:333-7.
23. Takahashi H, Chiu HC, Bandera CA, Behbakht K, Liu PC, Couch FJ, et al. Mutations of the BRCA2 gene in ovarian carcinomas. Cancer Res 1996; 56:2738-41.
24. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
25. Cliby W, Ritland S, Hartmann L, Dodson M, Hailing KC, Kenney G, et al. Human epithelial ovarian cancer allelotype. Cancer Res 1993;53: 2393-8.
26. Yang-Feng TL, Li S, Han H, Schwartz PE. Frequent loss of heterozygosity on chromosomes Xp and 13q in human ovarian cancer. Int J Cancer 1992; 52:575-80.
27. Cheng PC, Gosewehr JA, Kim TM, Velicescu M, Wan M, Zheng J, et al. Potential role of the inactivated X chromosome in ovarian epithelial tumor development. J Natl Cancer Inst 1996;88:510-18.
28. Osborne RJ, Leech V. Polymerase chain reaction allelotyping of human ovarian cancer. Br J Cancer 1994;69:429-38.
29. Parolini O, Ressmann G, Haas OA, Pawlowsky J, Gadner H, Knapp W, et al. X-linked Wiskott-Aldrich syndrome in a girl. N Engl J Med 1998;338: 291-5.
30. Buller RE, Skilling JS, Kaliszewski S, Niemann T, Anderson B. Absence of significant germ line p53 mutations in ovarian cancer patients. Gynecol Oncol 1995;58:368-74.
31. Skilling JS, Powills K, Lager DJ, Anderson B, Sorosky J, Buller RE. p53 allelotypes and enhanced detection of allelic loss in ovarian cancer: lack of correlation with familial and clinical factors. Gynecol Oncol 1996;61: 180-8.
32. Mutter GL, Chaponot ML, Fletcher JA. A polymerase chain reaction assay for non-random X chromosome inactivation identifies monoclonal endometrial cancers and precancers. Am J Pathol 1995;146:501-8.
33. Mutter GL, Boynton KA. PCR bias in amplification of androgen receptor alleles, a trinucleotide repeat marker used in clonality studies. Nucleic Acids Res 1995;23:1411-8.
34. Buller RE, Skilling JS, Sood AK, Plaxe S, Baergen RN, Lager DJ. Field cancerization: why late recurrent ovarian cancer is not recurrent. Am J Obstet Gynecol 1998;178:641-9.
35. Lallas TA, Buekers TE, Buller RE. BRCA1 mutations in familial ovarian cancer. Submitted.
36. International Federation of Gynecology and Obstetrics (FIGO). Changes in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 1987;156:263-4.
37. Lallas TA, Buller RE. Optimization of PCR and electrophoresis conditions enhances mutation analysis of the BRCA1 gene. Mol Genet Metab 1998; 64:173-6.
38. Belmont JW. Clinical interpretation of skewed X inactivation. Blood 1994; 84:2375-6.
39. Gale RE, Linch DC. Interpretation of X-chromosome inactivation patterns. Blood 1994;84:2376-8.
40. Fey MF, von Rohr A. Response. Blood 1994;84:2377-8.
41. Fey MF, Liechti-Gallati S, von Rohr A, Borisch B, Theilkas L, Schneider V, et al. Clonality and X-inactivation patterns in hematopoietic cell populations detected by the highly informative M27 beta DNA probe. Blood 1994;83:931-8.
42. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994;343:692-5.
43. Gale RE, Wheadon H, Boulos P, Linch DC. Tissue specificity of X-chromosome inactivation patterns. Blood 1994;83:2899-905.
44. McLaren A. Numerology of development. Nature 1972;239:274-6.
45. Holt JT, Thompson ME, Szabo C, Robinson-Benion C, Arteaga CL, King MC, et al. Growth retardation and tumour inhibition by BRCA1. Nat Genet 1996;12:298-302.
46. Schmidt M, Certoma A, Du Sart D, Kalitsis P, Leversha M, Foster K, et al. Unusual X chromosome inactivation in a mentally retarded girl with an interstitial deletion Xq27: implications for the fragile X syndrome. Hum Genet 1990;84:347-52.
47. Clarke JT, Greer WL, Strasberg PM, Pearce RD, Skomorowski MA, Ray PN. Hunter disease (mucopolysaccharidosis type II) associated with unbalanced inactivation of the X chromosomes in a karyotypically normal girl. Am J Hum Genet 1991;49:289-97.
48. Clarke JT, Wilson PJ, Morris CP, Hopwood JJ, Richards RI, Sutherland GR, et al. Characterization of a deletion at Xq27-q28 associated with unbalanced inactivation of the nonmutant X chromosome. Am J Hum Genet 1992;51:316-22.
49. Dahl N, Hu LJ, Chery M, Fardeau M, Gilgenkrantz S, Nivelon-Chevallier A, et al. Myotubular myopathy in a girl with a deletion at Xq27-q28 and unbalanced X inactivation assigns the MTM1 gene to a 600-kb region. Am J Hum Genet 1995;56:1108-15.
50. Rainier S, Feinberg AP. Genomic imprinting, DNA methylation, and cancer. J Natl Cancer Inst 1994;86:753-9.
51. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983;301:89-92.
52. Jones PA. DNA methylation errors and cancer. Cancer Res 1996;56: 2463-7.
53. Brown CJ. Role of the X chromosome in cancer. J Natl Cancer Inst 1996; 88:480-2.
54. Chenevix-Trench G, Kerr J, Hurst T, Shih YC, Purdie D, Bergman L, et al. Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms: clinicopathological correlations. Genes Chromosomes Cancer 1997;18:75-83.
55. Shih YC, Kerr J, Hurst TG, Khoo SK, Ward BG, Chenevix-Trench G. No evidence for microsatellite instability from allelotype analysis of benign and low malignant potential ovarian neoplasms. Gynecol Oncol 1998;69: 210-3.
56. Teneriello MG, Ebina M, Linnoila RI, Henry M, Nash JD, Park RC, et al. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 1993;53:3103-8.
57. Mok SC, Bell DA, Knapp RC, Fishbaugh PM, Welch WR, Muto MG, et al. Mutations of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 1993;53:1489-92.
58. Present address: J. S. Skilling, Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, University of California, Davis Medical Center, Sacramento, CA.